W. Schuyler Jones

Mar 28, 2024 | jamanetwork.com | Jiun-Ruey Hu |Yasser Jamil |Michelle D. Kelsey |W. Schuyler Jones

Key PointsQuestion  What is the optimal duration of dual antiplatelet therapy (DAPT) in terms of net adverse clinical events, major cardiovascular events, and bleeding for older adults after percutaneous coronary intervention (PCI)? Findings  In this systematic review and network meta-analysis of 14 randomized clinical trials, no differences in net adverse clinical events and major adverse cardiovascular events were seen for 1, 3, 6, and 12 months of DAPT.

Feb 22, 2024 | jacc.org | Jacob A. Udell |Mark C. Petrie |W. Schuyler Jones |Stefan Anker

Introduction Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of hospitalization for heart failure (HF) in patients with HF with reduced or preserved left ventricular ejection fraction (LVEF), type 2 diabetes and high cardiovascular risk, and chronic kidney disease.1 Patients with acute myocardial infarction (MI), especially those presenting with left ventricular systolic dysfunction (LVSD) or signs or symptoms of congestion, are at risk for in-hospital and long-term adverse...

Feb 22, 2024 | jacc.org | Jacob A. Udell |Mark C. Petrie |W. Schuyler Jones |Stefan Anker

Introduction Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of hospitalization for heart failure (HF) in patients with HF with reduced or preserved left ventricular ejection fraction (LVEF), type 2 diabetes and high cardiovascular risk, and chronic kidney disease.1 Patients with acute myocardial infarction (MI), especially those presenting with left ventricular systolic dysfunction (LVSD) or signs or symptoms of congestion, are at risk for in-hospital and long-term adverse...

Aug 25, 2023 | onlinelibrary.wiley.com | Josephine Harrington |Jacob A. Udell |W. Schuyler Jones |Stefan Anker

Introduction Despite improvements in therapies, patients with acute myocardial infarction (AMI) are at high risk for mortality and for developing heart failure (HF).1 This risk is particularly high for patients with reduced left ventricular ejection fraction (LVEF), acute signs and symptoms of congestion at the time of AMI, or with other risk factors such as advanced age, type 2 diabetes (T2D), or chronic kidney disease.

Aug 25, 2023 | onlinelibrary.wiley.com | Josephine Harrington |Jacob A. Udell |W. Schuyler Jones |Stefan Anker

Introduction Despite improvements in therapies, patients with acute myocardial infarction (AMI) are at high risk for mortality and for developing heart failure (HF).1 This risk is particularly high for patients with reduced left ventricular ejection fraction (LVEF), acute signs and symptoms of congestion at the time of AMI, or with other risk factors such as advanced age, type 2 diabetes (T2D), or chronic kidney disease.